Key result
Losartan and dapagliflozin combination therapy reduced uric acid levels by -284.43 µmol/L, compared to -229.62 µmol/L for losartan and -217.00 µmol/L for dapagliflozin monotherapy.
Why the study?
SGLT2 inhibitors and ARBs reduce serum uric acid, but few studies worldwide have evaluated their effectiveness in heart failure patients.
Does losartan and dapagliflozin combination therapy reduce serum uric acid levels compared to monotherapy in patients with heart failure?
Cross-Sectional (n=733)
No
Does losartan and dapagliflozin combination therapy reduce serum uric acid levels compared to monotherapy in patients with heart failure?
Mean Difference: -284.43
The combination of losartan and dapagliflozin provides superior uric acid reduction compared to either drug alone in patients with heart failure.
Combination therapy was associated with greater uric acid reduction in HF; hypothesis-generating and requires randomized confirmation.
Background: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors, and Angiotensin II Receptor Antagonists (ARBs) also have the effect of reducing serum uric acid but few studies worldwide assessed. Objective: Evaluate the effectiveness of serum uric acid lowering treatment of SGLT2 inhibitors, and ARB in heart failure (HF) patients. Methods: We conducted a cross-sectional analysis study with 8 weeks of follow-up on 733 heart failure (HF) patients treated at Can Tho Central General Hospital from January 2023 to March 2024. Patients enrolled in the study were examined and received losartan (Group A) or dapagliflozin (Group B) monotherapy or losartan and dapagliflozin combined therapy (Group C). The uric acid concentration group was defined into three subgroups with tertile 1 from smallest to quartile (Q) 1, tertile 2 from Q2 to Q3, and tertile 3 from Q3 to the largest value. Results: After 8 weeks of treatment, the uric acid reduction effect between groups A, B, and C showed that the combination group had the optimal reducing effect compared to losartan and dapagliflozin monotherapy with the mean difference being -229.62 ± 76.65 µmol/L, -217.00 ± 146.17 µmol/L, and -284.43 ± 136.32 µmol/L, respectively. In total, combination therapy showed the best reduction outcome in the population of male, female, patients with type 2 diabetes mellitus (T2DM), and dyslipidemia with the mean difference ranging from -226.21 ± 74.65 µmol/L to -231.85 ± 76.28 µmol/L and -209.62 ± 184.94 µmol/L to -225.75 ± 78.53 µmol/L and -273.02 ± 204.54 µmol/L to -308.93 ± 72.97 µmol/L in group A, B, and C, respectively. Conclusion: The optimal therapy for reducing uric acid levels in HF patients was the combination of losartan and dapagliflozin, and the effectiveness did not change through sex, T2DM, and dyslipidemia patients.
No takes yet. Share an insight, caveat, or question.
Huynh et al. (2024) conducted a cross-sectional in heart failure (n=733). losartan and dapagliflozin combined therapy vs. losartan or dapagliflozin monotherapy was evaluated on uric acid reduction (MD -284.43 µmol/L). Losartan and dapagliflozin combination therapy reduced uric acid levels by -284.43 µmol/L, compared to -229.62 µmol/L for losartan and -217.00 µmol/L for dapagliflozin monotherapy.